Digest Network Come funziona
Network
/
Società
Bo
Non verificato

Boehringer Ingelheim Limited

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

32 comunicati stampa

Guarda tutti i comunicati
28/11/2025
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim announces appointment to Board of Managing Directors
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
04/11/2025
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
29/10/2025
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
22/10/2025
Farmaceutica
Medicina Salute Benessere
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
17/10/2025
Farmaceutica
Medicina Salute Benessere
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
15/10/2025
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
09/10/2025
Farmaceutica
Medicina Salute Benessere
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
28/09/2025
Farmaceutica
Medicina Salute Benessere
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
01/09/2025
Farmaceutica
Medicina Salute Benessere
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
18/08/2025
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0